Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents

Guie Dong, Lysa Wang, Cong Yi Wang, Tianxin Yang, M. Vijay Kumar, Zheng Dong

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Inhibitors of histone deacetylases, including suberoylanilide hydroxamic acid (SAHA) and Trichostatin A, are a new class of anticancer agents. With potent chemotherapy effects in cancers, these agents are not obviously toxic in normal nonmalignant cells or tissues. However, their toxicity in kidney cells has not been carefully evaluated. Here, we demonstrate a potent apoptosis-inducing activity of SAHA in cultured renal proximal tubular cells. SAHA induces apoptosis at low micromolar concentrations. At 5 μM, SAHA induces 30 to ∼40% apoptosis in 18 h. The apoptosis is accompanied by notable caspase activation; however, the general caspase inhibitor VAD can only partially suppress SAHA-induced apoptosis, suggesting the involvement of both caspase-dependent and -independent mechanisms. SAHA treatment leads to cytochrome c release from mitochondria, which is suppressed by Bcl-2 but not by VAD. Bcl-2 consistently blocks SAHA-induced apoptosis. During SAHA treatment, Bcl-2 and Bcl-XL decrease, and Bid is proteolytically cleaved, whereas Bax and Bak expression remains constant. Bid cleavage, but not Bcl-2/Bcl-XL decrease, is completely suppressed by VAD. SAHA does not activate p53, and pifithrin-α (a pharmacological p53 inhibitor) does not attenuate SAHA-induced apoptosis, negating a role of p53 in SAHA-induced apoptosis. SAHA induces histone acetylation, which is not affected by VAD, Bcl-2, or pifithrin-α. Trichostatin A can also induce apoptosis and histone acetylation in renal tubular cells. Together, the results have shown evidence for renal toxicity of histone deacetylase inhibitors. The toxicity may be related to protein acetylation and decrease of antiapoptotic proteins including Bcl-2 and Bcl-XL.

Original languageEnglish (US)
Pages (from-to)978-984
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume325
Issue number3
DOIs
StatePublished - Jun 1 2008

Fingerprint

Histone Deacetylase Inhibitors
Antineoplastic Agents
Apoptosis
Kidney
trichostatin A
Acetylation
Caspases
Histones
vorinostat
Caspase Inhibitors
Histone Deacetylases
Poisons
Cytochromes c
Mitochondria
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. / Dong, Guie; Wang, Lysa; Wang, Cong Yi; Yang, Tianxin; Kumar, M. Vijay; Dong, Zheng.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 325, No. 3, 01.06.2008, p. 978-984.

Research output: Contribution to journalArticle

Dong, Guie ; Wang, Lysa ; Wang, Cong Yi ; Yang, Tianxin ; Kumar, M. Vijay ; Dong, Zheng. / Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents. In: Journal of Pharmacology and Experimental Therapeutics. 2008 ; Vol. 325, No. 3. pp. 978-984.
@article{ded6b6862c25464f89413510e98fac8a,
title = "Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents",
abstract = "Inhibitors of histone deacetylases, including suberoylanilide hydroxamic acid (SAHA) and Trichostatin A, are a new class of anticancer agents. With potent chemotherapy effects in cancers, these agents are not obviously toxic in normal nonmalignant cells or tissues. However, their toxicity in kidney cells has not been carefully evaluated. Here, we demonstrate a potent apoptosis-inducing activity of SAHA in cultured renal proximal tubular cells. SAHA induces apoptosis at low micromolar concentrations. At 5 μM, SAHA induces 30 to ∼40{\%} apoptosis in 18 h. The apoptosis is accompanied by notable caspase activation; however, the general caspase inhibitor VAD can only partially suppress SAHA-induced apoptosis, suggesting the involvement of both caspase-dependent and -independent mechanisms. SAHA treatment leads to cytochrome c release from mitochondria, which is suppressed by Bcl-2 but not by VAD. Bcl-2 consistently blocks SAHA-induced apoptosis. During SAHA treatment, Bcl-2 and Bcl-XL decrease, and Bid is proteolytically cleaved, whereas Bax and Bak expression remains constant. Bid cleavage, but not Bcl-2/Bcl-XL decrease, is completely suppressed by VAD. SAHA does not activate p53, and pifithrin-α (a pharmacological p53 inhibitor) does not attenuate SAHA-induced apoptosis, negating a role of p53 in SAHA-induced apoptosis. SAHA induces histone acetylation, which is not affected by VAD, Bcl-2, or pifithrin-α. Trichostatin A can also induce apoptosis and histone acetylation in renal tubular cells. Together, the results have shown evidence for renal toxicity of histone deacetylase inhibitors. The toxicity may be related to protein acetylation and decrease of antiapoptotic proteins including Bcl-2 and Bcl-XL.",
author = "Guie Dong and Lysa Wang and Wang, {Cong Yi} and Tianxin Yang and Kumar, {M. Vijay} and Zheng Dong",
year = "2008",
month = "6",
day = "1",
doi = "10.1124/jpet.108.137398",
language = "English (US)",
volume = "325",
pages = "978--984",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents

AU - Dong, Guie

AU - Wang, Lysa

AU - Wang, Cong Yi

AU - Yang, Tianxin

AU - Kumar, M. Vijay

AU - Dong, Zheng

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Inhibitors of histone deacetylases, including suberoylanilide hydroxamic acid (SAHA) and Trichostatin A, are a new class of anticancer agents. With potent chemotherapy effects in cancers, these agents are not obviously toxic in normal nonmalignant cells or tissues. However, their toxicity in kidney cells has not been carefully evaluated. Here, we demonstrate a potent apoptosis-inducing activity of SAHA in cultured renal proximal tubular cells. SAHA induces apoptosis at low micromolar concentrations. At 5 μM, SAHA induces 30 to ∼40% apoptosis in 18 h. The apoptosis is accompanied by notable caspase activation; however, the general caspase inhibitor VAD can only partially suppress SAHA-induced apoptosis, suggesting the involvement of both caspase-dependent and -independent mechanisms. SAHA treatment leads to cytochrome c release from mitochondria, which is suppressed by Bcl-2 but not by VAD. Bcl-2 consistently blocks SAHA-induced apoptosis. During SAHA treatment, Bcl-2 and Bcl-XL decrease, and Bid is proteolytically cleaved, whereas Bax and Bak expression remains constant. Bid cleavage, but not Bcl-2/Bcl-XL decrease, is completely suppressed by VAD. SAHA does not activate p53, and pifithrin-α (a pharmacological p53 inhibitor) does not attenuate SAHA-induced apoptosis, negating a role of p53 in SAHA-induced apoptosis. SAHA induces histone acetylation, which is not affected by VAD, Bcl-2, or pifithrin-α. Trichostatin A can also induce apoptosis and histone acetylation in renal tubular cells. Together, the results have shown evidence for renal toxicity of histone deacetylase inhibitors. The toxicity may be related to protein acetylation and decrease of antiapoptotic proteins including Bcl-2 and Bcl-XL.

AB - Inhibitors of histone deacetylases, including suberoylanilide hydroxamic acid (SAHA) and Trichostatin A, are a new class of anticancer agents. With potent chemotherapy effects in cancers, these agents are not obviously toxic in normal nonmalignant cells or tissues. However, their toxicity in kidney cells has not been carefully evaluated. Here, we demonstrate a potent apoptosis-inducing activity of SAHA in cultured renal proximal tubular cells. SAHA induces apoptosis at low micromolar concentrations. At 5 μM, SAHA induces 30 to ∼40% apoptosis in 18 h. The apoptosis is accompanied by notable caspase activation; however, the general caspase inhibitor VAD can only partially suppress SAHA-induced apoptosis, suggesting the involvement of both caspase-dependent and -independent mechanisms. SAHA treatment leads to cytochrome c release from mitochondria, which is suppressed by Bcl-2 but not by VAD. Bcl-2 consistently blocks SAHA-induced apoptosis. During SAHA treatment, Bcl-2 and Bcl-XL decrease, and Bid is proteolytically cleaved, whereas Bax and Bak expression remains constant. Bid cleavage, but not Bcl-2/Bcl-XL decrease, is completely suppressed by VAD. SAHA does not activate p53, and pifithrin-α (a pharmacological p53 inhibitor) does not attenuate SAHA-induced apoptosis, negating a role of p53 in SAHA-induced apoptosis. SAHA induces histone acetylation, which is not affected by VAD, Bcl-2, or pifithrin-α. Trichostatin A can also induce apoptosis and histone acetylation in renal tubular cells. Together, the results have shown evidence for renal toxicity of histone deacetylase inhibitors. The toxicity may be related to protein acetylation and decrease of antiapoptotic proteins including Bcl-2 and Bcl-XL.

UR - http://www.scopus.com/inward/record.url?scp=44249089268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249089268&partnerID=8YFLogxK

U2 - 10.1124/jpet.108.137398

DO - 10.1124/jpet.108.137398

M3 - Article

VL - 325

SP - 978

EP - 984

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 3

ER -